Last reviewed · How we verify
Topical NO
Topical NO is a nitric oxide-releasing formulation applied to the skin that promotes wound healing and tissue repair through vasodilation and antimicrobial effects.
Topical NO is a nitric oxide-releasing formulation applied to the skin that promotes wound healing and tissue repair through vasodilation and antimicrobial effects. Used for Chronic wounds (diabetic foot ulcers, venous leg ulcers), Acute wounds and surgical wounds.
At a glance
| Generic name | Topical NO |
|---|---|
| Also known as | Acidified Nitrite vs Placebo |
| Sponsor | University of Aberdeen |
| Drug class | Nitric oxide donor |
| Target | Nitric oxide pathway; soluble guanylate cyclase |
| Modality | Small molecule |
| Therapeutic area | Dermatology; Wound Care |
| Phase | FDA-approved |
Mechanism of action
Nitric oxide (NO) is a signaling molecule that enhances blood flow, reduces inflammation, and exhibits antimicrobial properties when delivered topically. The formulation releases NO directly at the wound site, stimulating angiogenesis, collagen deposition, and epithelialization while reducing bacterial colonization. This mechanism accelerates healing in chronic and acute wounds.
Approved indications
- Chronic wounds (diabetic foot ulcers, venous leg ulcers)
- Acute wounds and surgical wounds
Common side effects
- Local irritation or erythema
- Transient discomfort at application site
Key clinical trials
- Feasibility Study of Ocular Surface Squamous Neoplasia Surgical Excision in People Living With HIV in Sub-Saharan Africa (NA)
- Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT) (NA)
- Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- This Clinical Trial Aims to Compare the Effectiveness of Two Intra-pulpal Cryotherapy Techniques-Endo-ice and Ice Sticks-in Decreasing Intra-operative Pain and Enhancing the Success of Local Anesthesia During Pulpectomy of Mandibular Molars With Symptomatic Irreversible Pulpitis. (NA)
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (PHASE2)
- Virtual Reality for Port-a-Cath Access (NA)
- Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical NO CI brief — competitive landscape report
- Topical NO updates RSS · CI watch RSS
- University of Aberdeen portfolio CI